Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Baxdrostat + Dapagliflozin in Chronic Kidney Disease and Hypertension
NCT06268873Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2024
- Primary completion
- Feb 2028
- Modality
- Small Molecules
- Countries
- 38
01
Overview
Phase 3, randomised, double-blind trial of baxdrostat in chronic kidney disease (CKD) and hypertension (HTN) (2 arms), sponsored by AstraZeneca. Primary endpoint: Change in estimated Glomerular Filtration Rate at 116 weeks. Started Mar 2024; status: active, not recruiting.
02
Drugs
baxdrostat
03
Conditions
chronic kidney disease (CKD)hypertension (HTN)
Beyond the preview
Go deeper on NCT06268873.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06268873.